Cumberland reports top-line Phase 2a results for ifetroban in systemic sclerosis
The company said the ASSIST-SSc trial results support the drug's safety and tolerability in the rare disease population.
Cumberland Pharmaceuticals Inc. announced top-line results on October 23, 2026 from its Phase 2a trial of oral ifetroban in patients with systemic sclerosis. The announcement concerned top-line results from its Phase 2a ASSIST-SSc trial evaluating oral ifetroban for patients with systemic sclerosis.1
According to the company, the results support the safety and tolerability of ifetroban in this rare disease population.1
The filing, a Form 8-K dated October 23, 2026, did not include additional efficacy data or statistical detail beyond this summary statement. A copy of the release was furnished as Exhibit 99.1 to the filing.1
Cumberland Pharmaceuticals is based in Nashville, Tennessee, and trades on the NASDAQ Global Select Market under the ticker CPIX. The company's registered address is 1600 West End Avenue, Suite 1300, Nashville, Tennessee 37203, and its common stock, with no par value, is listed as CPIX on the NASDAQ Global Select Market.1
The report was signed by John Hamm, Chief Financial Officer of Cumberland. The filing was dated October 23, 2026 and signed by John Hamm, Chief Financial Officer.1
No further details on trial design, patient enrollment numbers, dosing regimen, or next steps for ifetroban's development in systemic sclerosis were disclosed in this filing.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.